Merck Takes $170 Million Charge for Discontinued Covid-19 Drug
(Bloomberg) -- Merck & Co. is taking a $170 million charge after discontinuing development of an experimental drug tested in patients hospitalized with severe and critical Covid cases, the company said in a quarterly filing.
In April, the drug giant announced that it was scrapping the intravenous therapy, called MK-7110, which was acquired in a $425 million deal in late November. The company had clinched a $356 million deal with the U.S. in December to deliver as many as 100,000 doses of MK-7110 by the end of June.
U.S. regulators told Merck early in 2021 that results from a small study weren't sufficient to seek clearance for the drug. At first, that prompted discussions about launching a new, large late-stage trial, according to Nick Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories.
But Merck announced on April 15 that it would abandon the intravenous product since it wouldn't have been available until the first half of 2022 because of additional research required to prove it works.
The protracted timeline and the need to focus on development for another drug, an antiviral pill called molnupiravir, were driving factors in abandoning development of the drug, Merck said. The company will no longer receive U.S. funding for supply, given the agreement was contingent on regulatory clearance.
The charge will be accounted for in Merck's first-quarter cost of sales, according to the filing Wednesday.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.